--- title: "Oramed Pharmaceuticals (ORMP) news: going concern" url: "https://aibio.space/companies/oramed-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ORMP going concern, convertible notes and buyback news: Oramed Pharmaceuticals files NT 10-Q, says March 31, 2026 quarterly report will be late." --- ORMP Oramed Pharmaceuticals Inc. NASDAQ · United States # Oramed Pharmaceuticals (ORMP) news ORMP going concern, convertible notes and buyback news Distress · 2026-05-15 ## [Oramed Pharmaceuticals files NT 10-Q, says March 31, 2026 quarterly report will be late](https://aibio.space/news/oramed-pharmaceuticals-files-nt-10-q-says-march-31-2026-quarterly/) Oramed Pharmaceuticals says it needs more time to finish the financial statements for the quarter ended March 31, 2026, and expects to file within five calendar days of the due date. Its 2025 annual report showed a $7,675,000 Scilex note due March 31, 2026, and going-concern warnings at two companies it has invested in. ## Latest Oramed Pharmaceuticals news 1. 2026-03-31 Mergers [Oramed closes Oratech sale to Lifeward for shares, warrants and revenue share](https://aibio.space/news/oramed-closes-oratech-sale-lifeward-shares-warrants-revenue-share/) Oramed Pharmaceuticals closed the sale of its Oratech subsidiary to Lifeward Ltd. on March 25, 2026, for 1,250,363 Lifeward ordinary shares, pre-funded warrants, warrants and a 4% revenue share on ReWalk products. The same day it bought $9,000,000 of Lifeward convertible notes, and Lifeward carries a going-concern warning of its own. 2. 2025-07-23 Financings [Oramed gives Scilex option to buy back warrants for $27,000,000](https://aibio.space/news/oramed-gives-scilex-option-buy-back-warrants-27-000-000/) Scilex will pay a $1,500,000 option fee in two installments. If the buyback is completed and paid in full, the maturity of the Tranche A Note moves to March 31, 2026. ## Oramed Pharmaceuticals at a glance - **Ticker**: ORMP - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $16.1 million ### Related companies - [Belite Bio](https://aibio.space/companies/belite-bio/) NASDAQ: BLTE - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) NASDAQ: ACAD - [Coherus Oncology](https://aibio.space/companies/coherus-oncology/) NASDAQ: CHRS - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) NASDAQ: MGRX - [Liquidia](https://aibio.space/companies/liquidia/) NASDAQ: LQDA - [Cumberland Pharmaceuticals](https://aibio.space/companies/cumberland-pharmaceuticals/) NASDAQ: CPIX - [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) NASDAQ: ATYR - [Artelo Biosciences](https://aibio.space/companies/artelo-biosciences/) NASDAQ: ARTL ### Also on NASDAQ - [Royalty Pharma](https://aibio.space/companies/royalty-pharma/) RPRX - [ANI Pharmaceuticals](https://aibio.space/companies/ani-pharmaceuticals/) ANIP - [Mobia Medical](https://aibio.space/companies/mobia-medical/) MOBI - [TG Therapeutics](https://aibio.space/companies/tg-therapeutics/) TGTX - [Valion Bio](https://aibio.space/companies/valion-bio/) VBIO - [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) PBLS ## What Oramed Pharmaceuticals does Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in research and development of oral delivery of therapeutic proteins. It has developed an oral dosage form designed to withstand the gastrointestinal tract and deliver active insulin or other proteins without chemically modifying them. The company intends to start a 60-patient, US-based clinical trial in the second half of 2026 to validate the robustness of its oral insulin formulation in a defined patient population, and OraTech will conduct the trial. OraTech was formed under a January 22, 2024 joint venture agreement with Hefei Tianhui Biotech Co., Ltd. (HTIT) to develop and commercialize oral insulin and POD technology using HTIT's manufacturing capabilities. The initial closing did not occur because HTIT did not satisfy the closing conditions, and on October 23, 2025 the company gave notice of termination of the joint venture agreement. Oramed also makes strategic investments in healthcare and life sciences companies and enters into real estate and financing transactions, including a Tranche A Note from Scilex Holding Company with a principal amount of $101,875,000. | Product or program | What it is | Stage | |---|---|---| | Oral insulin formulation | Oral dosage form for active insulin, planned US trial | 60-patient US trial planned for second half of 2026 | | POD technology | Platform for oral delivery of therapeutic proteins and vaccines | | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm). ## Oramed Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/) | | | Research and development | [$6.4 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/) | [$6.3 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/) | | Net income (loss) | [$64.0 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/) | [-$19.1 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/) | | Cash from operations | [-$9.1 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/) | [-$8.4 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/) | | Cash and equivalents | [$45.9 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026087361/) | [$54.4 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/) | | Short-term investments | [$5.4 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026087361/) | [$3.4 million](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $15.2 million, plus short-term investments of $846,000, $16.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Oramed Pharmaceuticals Has Oramed Pharmaceuticals issued a going-concern warning? Our latest story on this, dated May 15, 2026: "Oramed Pharmaceuticals files NT 10-Q, says March 31, 2026 quarterly report will be late". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oramed-pharmaceuticals-files-nt-10-q-says-march-31-2026-quarterly/). Has Oramed Pharmaceuticals sold convertible notes? Our latest story on this, dated Mar 31, 2026: "Oramed closes Oratech sale to Lifeward for shares, warrants and revenue share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oramed-closes-oratech-sale-lifeward-shares-warrants-revenue-share/). Does Oramed Pharmaceuticals have a share buyback? Our latest story on this, dated Jul 23, 2025: "Oramed gives Scilex option to buy back warrants for $27,000,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oramed-gives-scilex-option-buy-back-warrants-27-000-000/). What is the ticker symbol of Oramed Pharmaceuticals? Oramed Pharmaceuticals Inc. trades under the ticker ORMP on NASDAQ. Where is Oramed Pharmaceuticals listed? Oramed Pharmaceuticals Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:OJU1; LS:A1CTNU; TASE:ORMP. What is the SEC CIK of Oramed Pharmaceuticals? The SEC Central Index Key (CIK) for Oramed Pharmaceuticals Inc. is 1176309. Its filings are on SEC EDGAR. How many shares does Oramed Pharmaceuticals have outstanding? 41,597,354 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Oramed Pharmaceuticals listed under? Our directory records Oramed Pharmaceuticals Inc. under United States. What does Oramed Pharmaceuticals do? Our directory classifies Oramed Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Oramed Pharmaceuticals? The ISIN recorded for Oramed Pharmaceuticals Inc. is US68403P2039. Does aibio.space cover Oramed Pharmaceuticals? aibio.space lists Oramed Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Oramed Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Oramed Pharmaceuticals develop? Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in research and development of oral delivery of therapeutic proteins. It has developed an oral dosage form designed to withstand the gastrointestinal tract and deliver active insulin or other proteins without chemically modifying them. What is Oral insulin formulation from Oramed Pharmaceuticals? Oral insulin formulation: Oral dosage form for active insulin, planned US trial Stage: 60-patient US trial planned for second half of 2026. What is POD technology from Oramed Pharmaceuticals? POD technology: Platform for oral delivery of therapeutic proteins and vaccines Stage: stage not stated. ## Investor discussion: Oramed Pharmaceuticals Members talk about Oramed Pharmaceuticals (ORMP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Oramed Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390026057722/ea029019601-nt10q_oramed.htm) 2. 2026-03-31 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390026037474/ea0284244-8k_oramed.htm) 3. 2026-03-26 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm) 4. 2026-02-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000101297526000195/ormp-20260219.htm) 5. 2026-01-07 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390026001983/ea027192901ex99-1_oramed.htm) 6. 2025-11-17 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390025111298/ea026595901ex99-1_oramed.htm) 7. 2025-10-24 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390025101825/ea026231901ex99-1_oramed.htm) 8. 2025-07-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390025066819/ea0248817-8k_oramed.htm) 9. 2025-05-21 Financings Announced a share repurchase program. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390025046436/ea0243059-8k_oramed.htm) 10. 2025-04-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390025036109/ea023980001ex99-1_oramed.htm) 11. 2025-03-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1176309/000101376225003450/ea0234394-10k_oramed.htm) 12. 2025-03-03 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390025019437/ea0232721-8k_oramed.htm) 13. 2025-01-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390025005212/ea0228309-8k_oramed.htm) 14. 2024-12-17 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1176309/000121390024109825/ea0225149-8k_oramed.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ORMP on TradingView](https://www.tradingview.com/symbols/NASDAQ-ORMP/). ## SEC filings and registration - **SEC name**: Oramed Pharmaceuticals Inc. - **CIK**: 1176309 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ORMP (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036 - **Phone**: 646-844-1164 - **Shares outstanding**: 41,597,354 as of 2026-08-10 (10-Q filed 2026-08-10) - **Former names**: Integrated Security Technologies, Inc.; IGUANA VENTURES LTD ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1176309/000121390026100929/ea0305871-8k_oramed.htm) filed 2026-09-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1176309/000121390026087361/ea0300383-10q_oramed.htm) filed 2026-08-10 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1176309/000121390026084609/ea0297466-01.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1176309/000121390026073709/ea0296520-8k_oramed.htm) filed 2026-06-30 - [10-Q](https://www.sec.gov/Archives/edgar/data/1176309/000121390026059112/ea0290983-10q_oramed.htm) filed 2026-05-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1176309/000121390026037474/ea0284244-8k_oramed.htm) filed 2026-03-31 - [10-K](https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm) filed 2026-03-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1176309/000101297526000195/ormp-20260219.htm) filed 2026-02-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001176309), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Oramed Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ORMP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Oramed Pharmaceuticals Inc. - **Ticker**: ORMP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US68403P2039 - **Other listed symbols**: GETTEX:OJU1; LS:A1CTNU; TASE:ORMP - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ORMP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/oramed-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Oramed Pharmaceuticals (ORMP) news: going concern", 2026-10-31, https://aibio.space/companies/oramed-pharmaceuticals/